2020³â ¾ÆÁ¨´Ù
Cambridge Healthtech Institute¡¯s 15th Annual
Neurotech Investing & Partnering Conference
Á¦ÈÞ, ÅõÀÚ, Çù¾÷ °ü°è ±¸Ãà¿¡ ÀÇÇÑ ´º·ÎÅ×Å©³î·¯Áö ºÐ¾ß¿¡¼ÀÇ ¿¬±¸°³¹ß °¡¼Ó
2020³â 5¿ù 5-6ÀÏ
Neurotech Investing & Partnering Conference´Â ³ú¿Í ½Å°æ°èÀÇ »õ·Î¿î Ä¡·á¹ý ¹× Áø´Ü¹ý °³¹ß¿¡ Âü¿©Çϰí ÀÖ´Â ÅõÀÚÀÚ, ±â¾÷ ÀÓ¿ø, ±â¾÷°¡, ¿¬±¸ÀÚ µîÀÌ ÇÑÀÚ¸®¿¡ ¸ð¿© ¼Ò¼Ó Á¶Á÷°ú ¾÷°èÀÇ ÇâÈÄ ¹ßÀüÀ» À§ÇØ ÀǰßÀ» ±³È¯ÇÏ¸é¼ ±³·ùÇÏ´Â ±¹Á¦Àû Æ÷·³ÀÔ´Ï´Ù.
ÇâÈÄ ½ÃÀå µ¿Ç⠵ ´ëÇØ ³íÀÇÇÏ´Â ÀÌ ÄÁÆÛ·±½º¿¡¼´Â ´º·ÎÅ×Å©³î·¯Áö ¾÷°èÀÇ ÇöȲ¿¡ °üÇÑ ±âÁ¶ °¿¬, ÃÖ÷´Ü ¿¬±¸¿¡ ÁÖ·ÂÇϰí ÀÖ´Â ±â¾÷ÀÇ ÇÁ·¹Á¨Å×À̼Ç, ÁÖ¿ä Áß°³¿¬±¸(translational research) ÇÁ·ÎÁ§Æ®ÀÇ ¼Ò°³, ´º·ÎÅ×Å©³î·¯Áö ºÐ¾ßÀÇ ´Ù¾çÇÑ ÅäÇÈ¿¡ ÃÊÁ¡À» ¸ÂÃá ÆÐ³Î µð½ºÄ¿¼Ç µîÀÌ ÁøÇàµË´Ï´Ù.
Preliminary Agenda
State of the Neurotechnology Industry
Guest speakers provide an annual review of trends and developments in neuropharmaceuticals, neurodevices, and neurodiagnostics.
Speakers: Harry Tracy, PhD, President, NI Research
James Cavuoto, Editor & Publisher, Neurotech Reports
Investing in Neurotech Panel
A diverse panel of private, public and strategic investors will discuss their investment strategies. What does it take to get a neurotech company funded? What are the benefits and risks of business models
in devices, pharmaceuticals, diagnostics and information technology? What are today's deal terms and valuations? What are the best exit strategies and how is neurotech comparing to other industries?
Panelist: Laura Tadvalkar, Principal, MP Healthcare Venture Management (MPH)
Jamil Beg, Principal, 5AM Ventures
Tom Mathers, Partner, Pappas Capital
Wasim Malik, Partner, Iaso Ventures
Treatments for Alzheimer¡¯s and Cognitive Disorders
As the population ages, the market for neurodegenerative disorders is exploding. Current treatments stabilize symptoms only for a short period of time. What is on the horizon
for symptom improvement and disease modification from drug and device companies? Can earlier or more accurate diagnosis improve outcomes?
Speaker: Casey Lynch, CEO, Cortexyme
New Modalities in Epilepsy
Drugs and devices with novel mechanisms of action are on the horizon to decrease side effects and improve efficacy in epilepsy. Hear from leading companies on their approaches.
Moderator: Catherine Abbadie, PhD, Sr. Director, Business Development and Alliance Management, Sunovion
Speakers:
Ana Maiques, CEO, NeuroElectircs
Mark Lehmkuhle, CEO, Epitel
Internal and External Research and Development
Pharmaceutical and device companies are looking to provide complete solutions that span from prevention to treatment. Functions across the value chain will
be kept in house or partnered.
This panel of experts will discuss how they approach collaborations with other companies, academic groups, research institutes, and platform companies.
Moderator: Maria Shepherd, President, Medi-Vantage
Panelists:
Jeffrey Erb, Sr. Director, Strategy, and Business Development, Medtronic, Inc.
Bill Zeruld, Sr. Director, Alliance Management, Otsuka Pharmaceuticals
Parkinson¡¯s and Other Movement Disorders
Current treatments for movement disorders can improve functioning but suffer from side effects and ¡°off¡± periods especially as the disease progresses. A number of novel pipeline
pharmaceuticals and devices seek to address these issues. This session will explore how disease modifying treatments alter the course of movement disorders and how companion diagnostics can be leveraged to provide the most optimal outcomes for patients.
Moderator: Maria Shepherd, President, Medi-Vantage
Next-Generation Psychiatry
Schizophrenia, anxiety, depression, addiction, ADHD and other psychiatric
illnesses represent a large portion of the neurotech market. Development of promising next-generation treatments is challenging.
Novel devices and diagnostics are poised to change the treatment landscape. This session will gather the most innovative treatments for mental health disorders.
Moderator: Manuel Lopez Figueroa, Venture Partner, Bay City Capital
Speakers:
John Kaiser, CEO, Evecxia Therapeutics
David Baker, CEO, Vallon Pharmaceuticals
Targeting Orphan Diseases
Orphan disorders are a hot area of investment due to perceived benefits with regulatory agencies, ready access to patients, and premium pricing. This session will gather companies developing treatments
for ALS, lysosomal storage disorders, Huntington¡¯s, and more.
Super Session: Investing, Partnering and Licensing in Neurotech Panel
Big pharma, biotech and medtech need to act to capitalize new innovations that provide solutions to the global demands in healthcare. This insider panel will
discuss their areas of interest for investment, in-licensing novel therapeutics, devices and diagnostics and what they look for in a partner.
Panelists:
Olga Krylova, PhD, Director BD, Otsuka Pharmaceuticals
Valerie Photos, PhD, Operating Partner, Iaso Ventures
Beth Shafer, PhD, Head, Neuroscience Business Development, Takeda
* ÁÖÃÖÃø »çÁ¤¿¡ µû¶ó »çÀü ¿¹°í¾øÀÌ ÇÁ·Î±×·¥ÀÌ º¯°æµÉ ¼ö ÀÖ½À´Ï´Ù.